期刊
CLINICAL PHARMACOLOGY & THERAPEUTICS
卷 96, 期 2, 页码 214-223出版社
WILEY
DOI: 10.1038/clpt.2014.74
关键词
-
资金
- Bristol-Myers Squibb
Therapeutic antibodies that block the programmed cell death protein-1 (PD-1) immune checkpoint pathway prevent T-cell downregulation and promote immune responses against cancer. Several PD-1 pathway inhibitors have shown robust activity in initial trials.This article reviews the preclinical evidence, rationale, and clinical pharmacology of blockade of PD-1 or its ligands as therapy for lung cancer and provides an overview of agents in development, clinical evidence to date, and implications for clinical application.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据